ArticleAllergy2023
Validated allergen exposure chamber is plausible tool for the assessment of house dust mite-triggered allergic rhinitis.
Article in Allergy, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06778213 (A Randomized Placebo-controlled Double-blind Clinical Study for Evaluation of the Efficacy of Allergen-specific Immunotherapy Using Clinical and Biomarker Assessment in an Allergen Exposure Chamber and During Natural Exposure in Patients With House Dust Mite-triggered Allergic Rhinoconjunctivitis RANSES), which is not on this map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Randomized Placebo-controlled Double-blind Clinical Study for Evaluation of the Efficacy of Allergen-specific Immunotherapy Using Clinical and Biomarker Assessment in an Allergen Exposure Chamber and During Natural Exposure in Patients With House Dust Mite-triggered Allergic Rhinoconjunctivitis RANSES
Who cites it
12 citing papers in PubMed.
- Therapy of allergic rhinitis using ribavirin spray to clear nasal commensal viruses.Signal transduction and targeted therapy · 2026Trial
- High-affinity recombinant antibodies enable a sensitive MRGPRX2-specific ELISA for detecting allergic rhinitis and chronic spontaneous urticaria.Analytical and bioanalytical chemistry · 2026Article
- Association of ZNF608 Polymorphisms With House Dust Mite-Induced Allergic Rhinitis.Clinical and translational allergy · 2025Article
- Update on HDM Allergy: Principal Changes over the Years.International journal of molecular sciences · 2025Review
- Article
- Questionnaire for Clinical Diagnosis of House Dust Mite's Allergy Approved by Delphi Consensus.Clinical reviews in allergy & immunology · 2025Article
- An Indian Cross-Sectional Study to Evaluate In-Clinic Allergic Rhinitis Prevalence in Patients Having Nasal Symptoms Using the SFAR Questionnaire.Journal of asthma and allergy · 2025Article
- Plasma MRGPRX2 Correlates with Severity of Artemisia-Induced Allergic Rhinitis, Particularly in IgE-Negative Patients: A Cross-Sectional Study.Journal of asthma and allergy · 2025Article
- A Modern Approach to Clinical Outcome Assessment in Allergy Management: Advantages of Allergen Exposure Chambers.Journal of clinical medicine · 2024Review
- Immunological mechanisms of tolerance: Central, peripheral and the role of T and B cells.Asia Pacific allergy · 2023Review
- Validated allergen exposure chamber is plausible tool for the assessment of house dust mite-triggered allergic rhinitis.Allergy · 2023Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAllergen exposure chamber (AEC) is a clinical facility that allows exposure to allergenic airborne particles in controlled environment. Although AECs offer stable levels of airborne allergens, the validation of symptoms and other endpoints induced by allergen challenge is key for their recommendation as a plausible tool for the assessment of patients, especially in clinical research. This study aimed to demonstrate the reproducibility of defined clinical endpoints after AEC house dust mite (HDM) challenge under optimal conditions in patients with allergic rhinitis (AR).
methodHDM was distributed at different concentrations. The assessment was subjective by the patients: total nasal symptom score (TNSS), visual analog scale (VAS), and objective by the investigator: acoustic rhinometry, peak nasal inspiratory flow (PNIF), and nasal secretion weight. Safety was assessed clinically and by peak expiratory flow rate (PEFR) and forced expiratory volume in the first second (FEV
resultsConstant environment: temperature, humidity, and carbon dioxide (CO
conclusionHDM challenge in ALL-MED AEC offers a safe and reliable method for inducing symptoms in AR patients for the use in controlled clinical studies including allergen immunotherapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.